I
Ines Chevolet
Researcher at Ghent University Hospital
Publications - 22
Citations - 1061
Ines Chevolet is an academic researcher from Ghent University Hospital. The author has contributed to research in topics: Melanoma & Immune system. The author has an hindex of 14, co-authored 22 publications receiving 892 citations. Previous affiliations of Ines Chevolet include University of Zurich & Ghent University.
Papers
More filters
Journal ArticleDOI
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
TL;DR: Current available data on the role of IDO in cancer and the current results obtained with IDO inhibition are reviewed, both in animal models and in phase 1 and 2 clinical trials in humans.
Journal ArticleDOI
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial
Max Schreuer,Yanina Jansen,Simon Planken,Ines Chevolet,Teofila Seremet,Vibeke Kruse,Bart Neyns +6 more
TL;DR: Rechallenge with dabrafenib plus trametinib showed anti-tumour activity in patients who had previously progressed on BRAF inhibitors and as such, rechallenge represents a potential new treatment option for these patients.
Journal ArticleDOI
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
Max Schreuer,Geert Meersseman,Sari Van Den Herrewegen,Yanina Jansen,Ines Chevolet,Ambre Bott,Sofie Wilgenhof,Teofila Seremet,Bart Jacobs,Ronald Buyl,Geert Maertens,Bart Neyns +11 more
TL;DR: Quantitative analysis of BRAF V600mut ctDNA in plasma has unique features as a monitoring tool during treatment with BRAF/MEK inhibitors and its potential as an early predictor of acquired resistance deserves further evaluation.
Journal ArticleDOI
Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma
Ines Chevolet,Reinhart Speeckaert,Max Schreuer,Bart Neyns,Olga Krysko,Claus Bachert,Benjamin Hennart,Delphine Allorge,N. van Geel,M. Van Gele,Lieve Brochez +10 more
TL;DR: The expression of IDO, PD-L1, and CTLA-4 in the peripheral blood of melanoma patients is strongly interconnected, associated with advanced disease and negative outcome, independent of disease stage, and combination treatments targeting several of these markers are likely to exert a synergistic response.
Journal ArticleDOI
miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells.
Peter Dynoodt,Reinhart Speeckaert,Olivier De Wever,Ines Chevolet,Lieve Brochez,Jo Lambert,Mireille Van Gele +6 more
TL;DR: Evidence is provided that miR-145 is an invasion suppressor in metastatic melanoma cells and may serve as a useful therapeutic agent in melanoma when re-expressed in situ, despite the fact that it remains unclear which genes or pathways are regulated by miRNAs in melanomas.